Key result
Admission-derived inflammatory biomarkers are linked to MACE with moderate discrimination but lack 12-month prognostic value.
Why the study?
Inflammatory biomarkers derived from routine blood counts reflect immune activation in AMI, but their temporal prognostic relevance after AMI remains uncertain.
Do admission-derived inflammatory biomarkers predict major adverse cardiovascular events in patients with acute myocardial infarction?
Cohort (n=100)
Do admission-derived inflammatory biomarkers predict major adverse cardiovascular events in patients with acute myocardial infarction?
Effect estimate: AUC ≈0.69
p-value: p=0.032
Admission-derived inflammatory biomarkers show a dynamic prognostic profile after AMI, but their independent prognostic value is attenuated when adjusted for the GRACE score.
Biomarker associations with post-AMI outcomes attenuate after GRACE adjustment and lack consistency at 12 months; hypothesis-generating for early risk stratification in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Mitsis et al. (2026) conducted a cohort in Acute myocardial infarction (AMI) (n=100). Admission-derived inflammatory biomarkers was evaluated on Major adverse cardiovascular events (MACEs) cumulatively during hospitalization and at 1, 6, and 12 months (AUC ≈0.69, p=0.032). Admission-derived inflammatory biomarkers were associated with major adverse cardiovascular events with moderate discrimination (AUC ≈0.69, p=0.032), but lacked consistent prognostic value at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: